Still, he said Comvita was well positioned over the longer term through strategic partnerships which secure supply of its raw products and the sale of its products within China through its joint venture with China Resources which is due to start in July.
Comvita said it was investing in diversifying its product range, and had developed 14 new products since June 2016 with a further 10 products in the pipeline, scheduled for launch between March and June this year.
Coulter reiterated that the honey season this year was likely to be hurt by poor weather conditions.
"We will not have full visibility on our 2017 honey harvest until April/May 2017," he said. "Assuming a return to normal weather patterns next year, the operating profit impact of this poor honey harvest will be isolated to this current financial year."
To help improve its finances, Comvita has reduced its operating cost base by $6.5m in the first half of its financial year, and expects full year savings will be $10m lower than the previous year.
The company said the sale of its Medihoney brand to Derma Sciences will help it reduce debt to $53m as at March 31, 2017, from $82m at December 31, 2016. It retains the rights to use the brand in over-the-counter channels, and said it has inked new manufacturing agreements which will help lower costs.
Comvita will pay a first-half dividend of 2 cents per share on March 21, down from the 6 cent payment a year earlier.
Its shares slipped 0.7 per cent to $6.85.